Emerging nanoparticle formulations co-delivering siRNA against PTP1B and mRNA encoding insulin have shown enhanced β-cell viability and function in T2D rodent models, suggesting a future for hybrid non-viral delivery systems in combinatorial gene therapy strategies [57]. The gene discussed is INS; the disease is type 2 diabetes mellitus.